A ngina pectoris is chest discomfort experienced by patients with obstructive coronary artery disease (CAD) when the demand for oxygenated blood exceeds the supply. First-line therapies for symptoms consist of lifestyle modifications, such as weight loss and smoking cessation, and medications, including antiplatelet therapy, ␤-blockers, calcium channel blockers and nitrates, which act primarily by reducing demand. If these measures fail to sufficiently alleviate anginal symptoms, then revascularization via percutaneous coronary interventions (PCI), such as angioplasty and stenting, or coronary artery bypass grafting (CABG), can be considered in order to improve blood supply.
A ngina pectoris is chest discomfort experienced by patients with obstructive coronary artery disease (CAD) when the demand for oxygenated blood exceeds the supply. First-line therapies for symptoms consist of lifestyle modifications, such as weight loss and smoking cessation, and medications, including antiplatelet therapy, ␤-blockers, calcium channel blockers and nitrates, which act primarily by reducing demand. If these measures fail to sufficiently alleviate anginal symptoms, then revascularization via percutaneous coronary interventions (PCI), such as angioplasty and stenting, or coronary artery bypass grafting (CABG), can be considered in order to improve blood supply.
As therapies for CAD and acute myocardial infarction (MI) have successfully reduced mortality, the population of pa-tients with refractory angina has grown. [1] [2] [3] [4] Current estimates indicate that 850,000 patients in the United States have refractory angina. 1, [5] [6] [7] Affected individuals have exhausted the conventional therapeutic armamentarium, yet continue to experience disabling angina and are left with limited therapeutic options. Typically, revascularization is no longer possible because of a lack of suitable conduit vessels or the diffuse nature of the coronary disease. Therefore, new therapies for refractory angina are urgently needed.
Emerging evidence indicates that disease of the coronary microcirculation can contribute independently to symptoms and dysfunction in patients with CAD and, therefore, that the microcirculation is a suitable therapeutic target for treatment of ischemic disease. 4, 8, 9 Preclinical studies have shown that human CD34ϩ cells can stimulate neovascularization in ischemic tissue, 10 -12 thereby increasing capillary density and improving function in models of acute and chronic myocardial ischemia. A phase I/IIa study of 24 patients provided early evidence of the feasibility, safety, and bioactivity of autologous CD34ϩ cells when administered by percutaneous, intramyocardial injection and supported further clinical development of this treatment strategy. 13 
Methods
The ACT34-CMI study was a prospective, double-blind, randomized, controlled clinical trial conducted at 26 centers in the United States. The primary objective of this phase II clinical trial was to test the hypothesis that intramyocardial injection of autologous CD34ϩ cells will reduce the frequency of angina episodes in subjects with chronic severe refractory angina. The institutional review board at each center approved the protocol, and all patients provided written informed consent. Baxter Healthcare sponsored the study and was responsible for the conduct of the investigation, with oversight provided by the principal investigator and the scientific advisory board. Safety data were monitored by an independent Data Safety Monitoring Board (Online Appendix I, available at http://circres.ahajournals.org), and a Clinical Endpoints Committee adjudicated major adverse cardiovascular endpoints (MACE). The principal investigator had full access to the raw data.
Study Population
Entry criteria included patients ages 21 to 80 years with Canadian Cardiovascular Society (CCS) class III-IV chronic refractory angina despite optimum medical management, including maximally tolerated doses of ␤-blockers, nitrates, and calcium-channel blockers, and with no suitable revascularization options. Each patient's case and most recent angiogram was reviewed by an interventional cardiologist and cardiac surgeon who were not part of the study team to verify the lack of revascularization options. Single photon emission computed tomography (SPECT) imaging was required to document the presence of reversible ischemia. Patients were required to walk a minimum of 3 minutes but no longer than 10 minutes on a modified Bruce protocol exercise tolerance test (ETT) and had to experience angina or their angina equivalent during exercise testing. Exclusion criteria included left ventricular ejection fraction Ͻ25%, predominant congestive heart failure symptoms, MI within 60 days (creatine kinase-MB Ͼ3 times normal) of study entry, a successful or partially successful coronary revascularization procedure within the previous 6 months, placement of a biventricular pacemaker for cardiac resynchronization therapy for heart failure in the previous 90 days, and others (Online Appendix II for full inclusion and exclusion criteria).
Study Design, Cell Mobilization, Collection, and Preparation
Under normal conditions, the number of circulating CD34ϩ cells is too low to achieve the desired doses of cells by peripheral collection. Accordingly, granulocyte colony stimulating factor (G-CSF) (Filgrastim/Neupogen, Amgen, Thousand Oaks, CA) was administered to increase the number of circulating CD34ϩ cells for subsequent collection via leukapheresis. To maintain the double-blind design, all subjects (regardless of treatment group) underwent mobilization with 5 g/kg per day doses of G-CSF administered subcutaneously for 4 or 5 days, and leukapheresis was performed on the 5th day. On the following day, the mononuclear cell preparation collected during leukapheresis was enriched for CD34ϩ cells by using a commercially available device (Isolex 300i Magnetic Cell Selection System, Baxter Healthcare, Deerfield, IL). Lot release testing was performed on the final cell preparation to document sterility (Gram's stain and subsequent culture), viability (7-AAD apoptosis staining), 14 and purity (fluorescence-activated cell sorting for CD34ϩ cells).
Patients were randomly assigned to 1 of the 3 treatment groups via telephone call-in and an interactive voice-response system (IVRS). The cell-processing laboratory at each center was responsible for making the randomization call and preparing the CD34ϩ cells or control injection accordingly. Syringes containing cells or the control solution were identical in appearance.
Cell Injection Procedure
When all lot-release criteria were met (negative Gram's stain, viability Ն70%, CD34ϩ Ն50%), subjects were brought to the catheterization laboratory, where electromechanical endocardial mapping [15] [16] [17] was performed with the NOGA Map system (Biologics Delivery Systems, Diamond Bar, CA) as previously described 13 to identify viable, ischemic areas of the myocardium where CD34ϩ cells or placebo treatment would be delivered. Patients were randomized in a 1:1:1 ratio to receive 1ϫ10 5 CD34ϩ cells/kg body weight, 5ϫ10 5 (Ϯ10%) CD34ϩ cells/kg body weight (adjusted to a maximum of 100 kg), or placebo injection, which consisted of the identical diluent used for delivery of the CD34ϩ cells. The total cell dose was diluted in 2 cc of 0.9% NaCl (saline) plus 5% autologous plasma and was delivered via intramyocardial injection into 10 distinct sites (0.2 cc/site) with a NOGA Myostar catheter.
Endpoints
The prespecified primary efficacy end point was angina frequency 6 months after treatment. Angina frequency was documented by interactive voice responsive system (IVRS) on a daily basis for 28 days at baseline and at the 3-, 6-, and 12-month follow-up visits. Patients contacted the IVRS by telephone daily for 28 days prior to each visit and received a reminder call if they failed to call in. Patients who missed more than 3 calls during baseline screening would have been dropped from the study, but no patients were withdrawn for this reason. 
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the combined rate of major adverse cardiac events events, SPECT, and cardiac magnetic-resonance imaging (in a substudy). Safety endpoints included adverse event reporting, chest X-ray and echocardiography (to assess for complications related to the injection procedure), and laboratory screening.
Statistical Analysis
Statistical analysis was performed by statisticians employed by Baxter Healthcare; the raw data were also transferred to the investigators for independent analysis. The targeted enrollment of 150 patients was based on the results of the phase I/IIa study and was calculated to provide 90% power to detect a difference in angina frequency of 3 to 6 (0.75 standard deviations) episodes per week. The primary analysis was performed according to the intention to treat principle. Angina frequencies are displayed as least squares means of the number of angina episodes per week Ϯ the standard error of the least squares means. Other continuous variables are displayed as meanϮSD. The primary efficacy end point was a decline in angina frequency from baseline to month 6; summaries of both 6-and 12-month results are presented here. Log-linear modeling (Poisson regression) was performed on the frequency of angina at 6 and 12 months. Initially, the raw baseline value was used as the covariate. On review of the distribution of angina counts, it became clear that a more appropriate analysis was to use the log of the baseline value as a covariate, and the results of this analysis are presented here. The independent parameters in the model were treatment group, visit (6 and 12 months), and the interaction of treatment and visit. Exercise testing was evaluated using analysis of variance with repeated measures. The independent parameters in the model were treatment group, visit (6 and 12 months), and the interaction of treatment and visit. The raw baseline value was used as covariate. Robust standard errors for a repeated-measures analysis of both the angina frequency data and exercise tolerance times were used to safeguard against possible misspecification of the assumed correlation structure among repeated measurements. Categorical variables were compared with Fisher's exact test. Additional details are provided in Online Appendix II.
Results

Enrollment and Patient Disposition
Between April 2006 and March 2008, 26 centers across the United States enrolled 321 patients. At the end of the screening period, 147 patients failed to meet eligibility criteria and were withdrawn. The remaining 174 subjects began cell mobilization with G-CSF. Of these, 6 subjects withdrew before randomization for a variety of reasons ( Figure 1 ). Of the 168 subjects who were randomized, 1 subject was withdrawn because a thrombus was observed on a pigtail catheter on removal, and 1 subject died after cardiac perforation and tamponade during the injection procedure. Thus, 166 subjects were available for follow-up, of whom 162 and 156 subjects completed the 6-and 12-month follow-up visits, respectively (Figure 1 ). During the course of the study, site monitoring raised questions in regard to certain data at 1 study site. It was decided to exclude the 7 subjects enrolled at this site from the analyses of the efficacy data, while retaining all safety information. This decision did not change the overall study results nor materially alter the statistical significance of the analyses.
Baseline Characteristics
Patient baseline characteristics were similar in all 3 treatment groups ( Table 1 ). The total patient population included 22 (13%) females and 145 (87%) males with a mean age of 61Ϯ8.9 (range 41 to 91) years. Previous CABG had been performed in 93% of subjects, and the mean number of CABG operations per subject was 1.4Ϯ0.6 (range 0 to 4).
Previous PCI had been performed in 83% of patients, and the mean number of prior PCI procedures was 2.9Ϯ3.1 (range 0 to 23) per subject. The study groups were similar with regard to age, weight, gender, race, smoking history, diabetic status, and cardiac status, although the control group had a higher percentage of subjects with a history of congestive heart failure.
Cell Mobilization and Apheresis
Administration of G-CSF was associated with bone pain in 20.1% of subjects, with angina in 17.4%, and with congestive heart failure in 2 patients. Eight subjects had troponin elevations that were consistent with a non-ST segment elevation MI by the new universal definition of MI 18, 19 ; 3 of these subjects were withdrawn from the study, including 1 subject whose troponin level was 1.2 times the upper limit of normal. One subject was withdrawn because of a left-ventricular thrombus noted on cardiac echo, 1 subject underwent coronary revascularization, 1 was hospitalized for an acute coronary syndrome, and 2 were withdrawn at the discretion of the local investigator.
CD34ϩ cell selection resulted in a cell product with the following composition: CD34ϩ83.0%Ϯ14.6%, B cells 11.3%Ϯ12.5% and T cells 1.0%Ϯ2.3%.
Intramyocardial Injection Procedure
Endocardial mapping was performed in 168 patients. In 1 subject, a thrombus was observed on the mapping catheter tip when it was removed from the patient, and this patient was withdrawn from the study by the investigator (as noted under Enrollment and Patient Disposition). Intramyocardial injection procedures were safely accomplished in 165 of the remaining 167 subjects. Two subjects experienced an apparent myocardial perforation: 1 resulted in hemothorax that was treated successfully, and the 2nd resulted in cardiac tamponade. In the 2nd case, a pericardiocentesis procedure was unsuccessful, and the patient died.
A total of 47 (28%) subjects had elevated troponin levels (mean 1.27Ϯ4.73) at some point during the mobilization and injection period, all of which were minor and subclinical except for those mentioned above.
Primary Outcome
At 6 months, the frequency of angina was significantly lower in patients treated with the low dose of CD34ϩ cells than in the control group (6.8Ϯ1.1 versus 10.9Ϯ1.2 episodes per week, Pϭ0.020) (Figure 2 ). Angina was also less frequent in the high-dose group (8.3Ϯ1.1 episodes per week) than in the control group, but the difference was not statistically significant (Pϭ0.167). At 12 months, the frequency of angina remained significantly lower in the low-dose group than in the control group (6.3Ϯ1.2 versus 11.0Ϯ1.2 episodes per week, Pϭ0.035) and lower (7.2Ϯ1.1), but not significantly (Pϭ0.181), in the high-dose group than in the control group. At 6-and 12-months follow-up, the antianginal regimen was unchanged in 86.8% and 84.5% of control and 90.4% and 85.8% of treated patients, increased in 4.3% and 5.5% control and 6.0% and 8.2% treated and decreased in 8.9% and 10% control and 3.7% and 5.9% treated patients. There was no statistical interaction between changes in any medication and changes in angina frequency or ETT time.
Exercise Tolerance Testing
Improvement in total exercise time at 6 months was significantly greater in the low-dose group than in the control group (139Ϯ151 versus 69Ϯ122 seconds, Pϭ0.014) (Figure 3) . The high-dose group also had greater improvement than was observed in the control group (110Ϯ155 seconds), but the difference was not statistically significant (Pϭ0.097). At 12 months, the low-dose group continued to show significantly greater improvement in total ETT time in comparison with the control group (140Ϯ171 versus 58Ϯ146 seconds, Pϭ0.017), and improvement in the high-dose patients (103Ϯ162 seconds) remained greater, but not significantly, than did improvement in the control group (Pϭ0.134).
All subjects had angina at baseline, as required by the inclusion criteria. At 6 months, the increase in time to the onset of angina during treadmill exercise was greater, but not significantly, in the low-dose group than in the control group (161Ϯ179 versus 87Ϯ208 seconds, Pϭ0.235). Change in time to angina onset in the high-dose group (87Ϯ208 seconds) and in the control group were similar. At 12 months, the difference between the low-dose and control groups was greater than at 6 months, but did not reach statistical significance (139Ϯ148 versus 57Ϯ168 seconds, Pϭ0.08).
Seattle Angina Questionnaire
At 6 months, the mean change in the Angina Stability Scale was 13.8Ϯ31.9 in control subjects, 29.8Ϯ30.1 in the lowdose group and 25.5Ϯ30.3 in the high-dose group (Pϭ0.290). The percentage of subjects who improved was 40.8 in the control group, 69.2 in the low-dose group (Pϭ0.005 versus the control group), and 67.3 in the high-dose group (Pϭ0.010 versus the control group). At 12 months, the mean change in the Angina Stability Scale was 14.4Ϯ32.4 in the control group, 24.0Ϯ32.3 in the low-dose group, and 21.0Ϯ36.2 in the high-dose group.
The Angina Frequency Scale showed only minor differences between control and treatment groups at 6 months 
CCS Class, Antianginal Medications
Trends in CCS class and antianginal medication use all favored the subjects treated with CD34ϩ cells. CCS class worsened from baseline to 6 months in 12.8% of control subjects, in comparison with 2.0% of low-dose subjects and 3.8% of high-dose subjects. At 6 months, the percentage of patients with an improvement in CCS class was greater in the treated groups (low dose: 62.8; high dose: 60.7) than in control subjects (53.1). At 12 months, the percentage of subjects whose CCS class had worsened from baseline remained greater in the control group (8.7) than in the low-dose (3.9) and high-dose (5.8) groups, whereas the percentage of subjects who experienced a Ն2-class improvement was greater in the low-dose (23.1) and high-dose (25.0) groups than in the control subjects (15.2) . Similarly, the mean reduction in nitroglycerine (NTG) tablet usage was greater in the treated groups than in control subjects at 6 months (low dose: Ϫ6.3Ϯ8.1; high dose: Ϫ7.3Ϯ9.9; control: Ϫ4.2Ϯ8.8 NTG tablets per day), although the differences between treated and control groups did not reach statistical significance; results were similar at 12 months.
SPECT Imaging
Adenosine SPECT imaging was performed at baseline and 6 and 12 months after injection. At 6 months, total severity score stress images showed a significant improvement in the low-dose group than in the control group (Ϫ117.4Ϯ221.2 versus ϩ0.1Ϯ161.1, Pϭ0.002). The remaining standard SPECT imaging parameters revealed no significant differences between treated and control groups.
Major Adverse Cardiovascular Events
There were 3 deaths in the study population, all of which occurred in the control group. Myocardial infarction occurred in 7 (12.5%) control-group patients, 3 (5.5%) low-dose-group patients, and 3 (5.4%) high-dose-group patients. When urgent revascularization, worsening congestive heart failure, and acute coronary syndrome were included as MACEs, there continued to be no evidence of harm associated with the intramyocardial injection of autologous CD34ϩ cells, and trends toward lower event rates were observed ( Table 2) .
Discussion
This phase II study, in which 167 "no-option" patients with refractory angina were enrolled, provides an opportunity to make observations regarding the feasibility, safety, and efficacy for a strategy of intramyocardial injection of autologous CD34ϩ. The primary findings of this study are that intramyocardial injection of autologous CD34ϩ cells was associated with a significant decrease in angina frequency and a significant improvement in exercise tolerance in patients with optimally managed but refractory angina. The significant benefit of the low dose of CD34ϩ cell therapy observed at the primary end point of 6 months was preserved and increased slightly in magnitude at 12 months, contrasting with prior studies of angiogenic therapies in which placebo "catch-up" was observed. 20 The overall improvement in low-dose-treated patients was also supported by positive trends in time to onset of angina, quality of life testing, nitroglycerine use, and CCS classification. Our findings are consistent with our pilot study 13 as well as other pilot trials of intramyocardial bone marrow cell injection in the setting of chronic myocardial ischemia. 21, 22 Notably, however, this is the first randomized, controlled trial of stem-cell therapy in patients with refractory angina to achieve significant improvements in both anginal frequency and exercise tolerance.
Another important observation that should not be overlooked is the demonstration of feasibility of this treatment strategy in this multicenter investigation. Each treatment required that cell mobilization, collection by leukapheresis, CD34ϩ-cell enrichment, and lot release testing, as well as NOGA-guided intramyocardial injection, be performed locally at the investigative site. Evidence that this complex protocol could be successfully implemented at multiple treatment centers was necessary before this therapeutic approach could be considered for use on a larger scale. Successful maintenance of the study blind was also critical for the development of a phase III study.
As with any new therapy, particularly in patients with advanced cardiovascular disease, safety is a key consideration. The overall occurrence of major adverse cardiac events was no higher in patients treated with CD34ϩ cells than in placebo-treated patients, and key safety indices tended to favor CD34ϩ-cell-treated subjects. The study was not powered to detect differences between groups in safety events, and consequently, these observations indicate only that there is currently no evidence for an increased risk of adverse cardiac events associated with intramyocardial CD34ϩ cell injection. As expected, G-CSF administration and the apheresis procedure were associated with adverse events in this patient population. 23 It is worth noting that the rate of enzyme elevation consistent with the new "universal" definition of MI (4.6%) observed in this study is substantially lower than that observed in 3 large meta-analyses of patients undergoing routine percutaneous intervention. 24 -26 Five subjects were withdrawn from the study following mobilization and apheresis because of events potentially, but not conclusively, attributable to these procedures. Future studies may be designed to determine whether alternate strategies for the collection of CD34ϩ cells, including the addition of rapidly acting mobilizing agents, 27 altered apheresis protocols, or bone marrow aspiration, are available and warranted. The safety of the intramyocardial injection procedure itself also requires careful consideration. The occurrence of 2 (1.2%) myocardial perforation events during the injection procedure is consistent with previous studies. 28 It is possible that the rate of adverse procedural events could decrease as the technique is used more routinely; nevertheless, this will remain an area of careful scrutiny as therapies requiring intramyocardial delivery of therapeutics are developed.
This study was not powered to detect differences in efficacy between the low-dose and high-dose groups. Nevertheless, patients who received the lower dose appeared to experience greater improvement in several end points. This lack of a definitive dose-dependent response was not anticipated, but is far from unprecedented, and is consistent with the results from preclinical studies of cell therapy for myocardial ischemia 29 and with an extensive body of literature indicating that the response to biological manipulations of angiogenesis is often biphasic. 30 Perhaps the most notable recent clinical example is a phase II study of the antiangiogenic drug bevacizumab 31 for treatment of metastatic colon cancer. The low-dose treatment, which was half the magnitude of the high-dose treatment, was associated with higher response rates and survival, and the subsequent successful phase III trial, which led to FDA approval of the drug for the condition studied, used the low dose. 32 No mechanism for the inverted dose-response relationship associated with bevacizumab has been described, and the mechanism responsible for the potentially more robust effect observed in patients treated with a lower dose of intramyocardially injected CD34ϩ cells is also unknown. One possible explanation is that the higher dose exceeded the (as yet unidentified) optimum cell density required for promoting paracrine effects within the confined space of the myocardium.
Perfusion imaging was performed in an attempt to quantify changes in blood flow. One SPECT assessment showed improvement in low-dose patients at 6 months, and the remaining SPECT parameters did not identify significant differences between treatment groups. Does this negate the possibility that changes in blood flow were responsible for the clinical effects observed? Not necessarily. SPECT imaging was designed and validated as a tool for detecting relative reductions in blood flow that result from the obstruction of epicardial coronary arteries, whereas the mechanism responsible for the benefit of CD34ϩ-cell therapy is believed to involve increases in capillary density and improved microcirculation in the area around the injection sites. These improvements are likely spread around throughout the ischemic zone of the myocardium, crossing the boundaries of the standard 17-segment SPECT map; thus, the ability to detect relative changes in blood flow would be, at best, limited. Newer methods for measuring perfusion, such as quantitative positron-emission tomography imaging, may be required to document changes in absolute blood flow at the microvascular level. 33 All MACE from start of mobilization to the end of the 12-month follow-up. MI, myocardial infarction; worse CHF, worsening congestive heart failure; ACS, acute coronary syndrome.
a Includes all hospitalizations or emergency room (ER) visits that were cardiac related. This is based on adjudicated hospitalization and ER visit.
*P values calculated using Fisher exact test.
The limitations of this investigation include its status as a phase II study; thus, the findings of improvement following intramyocardial injection of autologous CD34ϩ cells must be replicated in a phase III investigation before definitive conclusions regarding efficacy can be made. Furthermore, the study was not powered to detect differences between doses, so observations regarding the apparently greater potency of the lower cell dose do not provide a conclusive assessment of the potential dose-response relationship.
In summary, the results from this phase II study support the safety and efficacy of intramyocardially injected autologous CD34ϩ cells for symptom reduction and improved exercise capacity in "no-option" patients with refractory angina. Larger-scale studies are warranted to verify these effects and to refine the methods for collecting and administering CD34ϩ cells to patients with disabling angina symptoms.
Novelty and Significance
What Is Known?
• Human CD34ϩ cells are well known as hematopoietic stem cells used for stem cell transplants in patients who have bone marrow ablation by chemotherapy or radiation therapy.
• The CD34ϩ cells can differentiate into hematopoietic lineage cells and reconstitute the bone marrow. In addition, they have also been shown to have endothelial lineage potential in vitro and in vivo.
• Preclinical studies in models of myocardial or limb ischemia show that local delivery of human CD34ϩ cells improves perfusion and function in ischemic tissue.
What New Information Does This Article Contribute?
• In a double-blind, randomized, controlled clinical trial, direct intramyocardial injection of autologous CD34ϩ cells was associated with an improvement of exercise tolerance and with reductions in angina frequency in 167 "no-option" patients with refractory angina.
• In addition to yielding data on safety and efficacy, the study also provides evidence that the strategy of mobilizing, collecting, purifying, and delivering autologous CD34ϩ cells in patients with severe cardiovascular disease is feasible at a large number of centers.
As interventions for acute myocardial infarction have reduced mortality in patients with coronary artery disease, and because medical treatment has also improved long-term outcomes, a growing population of patients with refractory ischemia is emerging. These individuals have exhausted medical, interventional, and surgical options and have persistent, lifestyle-limiting ischemic symptoms. Epicardial revascularization is no longer possible, often because of extensive disease or chronic total occlusion. In addition to the loss of major conduit vessels in these subjects, however, the attenuation of the microcirculation is also thought to contribute to the decrease in overall myocardial perfusion. The CD34ϩ cell population has been shown to be enriched in cells with the ability to stimulate neovascularization, both by contributing directly to vessel formation and by secreting proangiogenic factors. This report provides evidence from a double-blind study that direct injection of CD34ϩ cells into the ischemic myocardium reduces chest pain and significantly increases exercise tolerance in patients with refractory angina.
